June 30 — Lilly and Innovent Biologics (01801.HK) said they
文 / 小金
2026-06-30 12:50:03
来源:亚金网
June 30 — Lilly and Innovent Biologics (01801.HK) said they have agreed a commercialization deal for Lilly’s CDK4/6 inhibitor Verzenio (abemaciclib) in mainland China. Innovent will handle importation, sales, marketing and distribution in mainland China; Lilly will continue to be responsible for manufacturing, supply and ongoing development.
